drugset
drugset / Trial / NCT07198516

The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:

NCT07198516 ↗

Phase 0 Not yet recruiting 149 enrolled Fujian Medical University Union Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effect and safety of Henggliejin on fatty liver in type 2 diabetes patients with nonalcoholic fatty liver disease

Timeline

Start
2025-11-01
Primary completion
2026-09-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Hengge Liejing Unknown 10 mg Oral

Indications

NAFLD1 type 2 diabetes mellitus